Tonix Pharmaceuticals Holding Corp. (TNXP): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$99.84M

Year ended 2025-12-31

-$152.99M

Trailing 12 months to 2026-06-30

2010-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$99.84M	n/m	2026-03-12, From 2025-01-01
2024-12-31	-$60.92M	n/m	2026-03-12, From 2024-01-01
2023-12-31	-$102.00M	n/m	2025-03-18, From 2023-01-01
2022-12-31	-$98.05M	n/m	2024-04-01, From 2022-01-01
2021-12-31	-$75.56M	n/m	2023-03-13, From 2021-01-01
2020-12-31	-$48.57M	n/m	2022-03-14, From 2020-01-01
2019-12-31	-$26.68M	n/m	2021-03-15, From 2019-01-01
2018-12-31	-$23.97M	n/m	2020-03-24, From 2018-01-01
2017-12-31	-$19.13M	n/m	2019-03-18, From 2017-01-01
2016-12-31	-$37.31M	n/a	2018-03-09, From 2016-01-01
No annual figure between 2012-12-31 and 2016-12-31.
2012-12-31	-$5.71M	n/m	2013-11-22, From 2012-01-01
2011-12-31	-$2.64M	n/m	2013-11-22, From 2011-01-01
2010-12-31	-$1.23M	n/a	2012-03-30, From 2010-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Tonix Pharmaceuticals Holding Corp. (TNXP)	2025-12-31	-$99.84M	n/m
Evommune, Inc. (EVMN)	2025-12-31	-$76.44M	n/m
CV Sciences, Inc. (CVSI)	2025-12-31	-$407.0K	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	-$11.0K	n/m
Pyxis Oncology, Inc. (PYXS)	2025-12-31	-$63.50M	n/m
Arbutus Biopharma Corp (ABUS)	2025-12-31	-$39.64M	n/m
Prelude Therapeutics Inc (PRLD)	2025-12-31	-$56.30M	n/m
Opus Genetics, Inc. (IRD)	2025-12-31	-$35.25M	n/m
Jaguar Health, Inc. (JAGX)	2025-12-31	-$23.69M	n/m

Compare TNXP, EVMN, CVSI, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗